Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Caribou Biosciences (CRBU) EPS (Weighted Average and Diluted) (2021 - 2025)

Caribou Biosciences (CRBU) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with -$0.28 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 28.21% to -$0.28 in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.35, a 18.18% increase, with the full-year FY2025 number at -$1.59, up 3.64% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.28 for Q4 2025 at Caribou Biosciences, up from -$0.3 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.09 in Q4 2021 to a low of -$1.39 in Q2 2021.
  • A 5-year average of -$0.42 and a median of -$0.42 in 2022 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): tumbled 600.0% in 2022, then surged 72.73% in 2023.
  • Caribou Biosciences' EPS (Weighted Average and Diluted) stood at $0.09 in 2021, then crashed by 600.0% to -$0.45 in 2022, then increased by 28.89% to -$0.32 in 2023, then dropped by 21.87% to -$0.39 in 2024, then rose by 28.21% to -$0.28 in 2025.
  • Per Business Quant, the three most recent readings for CRBU's EPS (Weighted Average and Diluted) are -$0.28 (Q4 2025), -$0.3 (Q3 2025), and -$0.51 (Q2 2025).